Latest Regulatory Filings News

Newmont Corporation’s 2024 Annual Report reveals a robust financial performance fueled by higher metal prices and the strategic acquisition of Newcrest Mining. The company also embarks on a major portfolio reshaping with planned divestitures of six non-core assets.

Zelira Therapeutics has received a $1.15 million cash refund from the Australian Government’s R&D Tax Incentive Scheme, bolstering its working capital to advance clinical development and business operations.

Far Northern Resources has amended its December 2024 Appendix 5B cash flow report to provide clearer details on investing activities, revealing a net cash outflow and a modest cash balance at quarter-end.

Neurizon Therapeutics received FDA guidance on its IND application for NUZ-001, with a single request for additional animal exposure data but no safety concerns flagged. The company is actively addressing the FDA’s request while evaluating impacts on its ALS trial timeline.

Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.

Laramide Resources Ltd. has acknowledged a delayed filing of a director's interest notice due to internal illness, prompting an ASX inquiry and procedural upgrades to prevent future lapses.

Artrya Limited has secured A$15 million through a two-tranche placement aimed at accelerating regulatory approvals and commercial rollout of its Salix® coronary artery disease diagnostic software in the US.

Predictive Discovery Limited has successfully completed a A$69.2 million strategic placement with key investors Lundin family and Zijin Mining Group, strengthening its financial position for future growth.

Pro-Pac Packaging has updated its quarterly cash flow report, highlighting a net cash outflow from operations and outlining plans to improve margins and secure longer-term funding.

Inventis Limited updates its operational review with corrected financials, securing major orders and pursuing significant capital raises to fuel international expansion.

BlinkLab has secured North Shore Pediatric Therapy as the second US clinical site in its autism diagnostic study, enhancing recruitment and data quality with a leading Chicago-based specialist.

CLINUVEL has released preliminary data from its CUV052 study showing SCENESSE® is well tolerated in adolescent erythropoietic protoporphyria (EPP) patients, supporting a planned label extension in 2025.